Pulmonary Hypertension (PH)

Pulmonary Hypertension (PH) is a disease of the pulmonary vasculature, leading to shortness of breath, dizziness, fainting, and ultimately right heart failure. A total of approximately 100 million people worldwide suffer from one of the forms of Pulmonary Hypertension. Vascular pathology is characterized by vasoconstriction of the pulmonary vessels and abnormal (pseudomalignant) remodeling processes (thickening) of all vessel layers. Excessive proliferation of the vascular smooth muscle cells (SMC) is a prominent feature in virtually all forms of the disease. These remodeling processes lead to a severe loss of the cross-sectional area of the vessels, vascular pruning, and a concomitant increase in right ventricular afterload. Current PH therapy provides symptomatic relief and improves prognosis but falls short when it comes to recovering structural and functional lung vascular integrity, a prerequisite for symptom-free long-term survival. Restoration of the vascular structure and function (reverse remodeling) is the main goal of the research work carried out by the PH team.

Scientific Coordinators of the Disease Area

Prof. Dr. H. Ardeschir Ghofrani (UGMLC)
Prof. Dr. Ralph T. Schermuly (UGMLC)

Administrative Coordinator of the Disease Area

Dr. Sylvia Weißmann (UGMLC)

Participating DZL Partner Sites


News about Pulmonary Hypertension (PH)

18. March 2020

EU promotes lung research at the Max Planck Institute in Bad Nauheim

Soni Savai Pullamsetti Receives 2 Million Euro Research Grant from the European Research Council.
Read More
26. April 2019

Dr. Astrid Weiß and Moritz Neubauer Honored with René Baumgart Award

Pulmonary Arterial Hypertension (PAH) is a progressive, fatal disease of the pulmonary vasculature. Affected patients have a poor prognosis, and treatment options are limited.
Read More
21. March 2019

Research Prizes for DZL Scientists at the 60th DGP Congress in Munich

The DZL was represented with an information desk at the 60th Congress of the German Respiratory Society (DGP), which took place in Munich from March 13–16, 2019.
Read More
All Pulmonary Hypertension (PH) news